Cardiometabolic abnormalities in the polycystic ovary syndrome: Pharmacotherapeutic insights

Pharmacology and Therapeutics

Volumn 119, Issue 3, 2008, Pages 223-241

  Westerveld, H E ^a   Hoogendoorn, M ^a   de Jong, A W F ^a   Goverde, A J ^a   Fauser, B C J M ^a   Dallinga Thie, G M ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Dyslipidemia; Lipoprotein metabolism; Pharmacotherapy; Polycystic ovary syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACIPIMOX; AROMATASE INHIBITOR; CLOMIFENE; COMPACTIN; CYPROTERONE ACETATE; DESOGESTREL PLUS ETHINYLESTRADIOL; EXENDIN 4; FINASTERIDE; FLUTAMIDE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SIMVASTATIN; SPIRONOLACTONE; TESTOSTERONE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TROGLITAZONE; UNINDEXED DRUG;

AMENORRHEA; ANOVULATION; ATHEROSCLEROSIS; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE MARKER; DRUG CONTRAINDICATION; DRUG INDICATION; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERANDROGENISM; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIVER TOXICITY; LOW DRUG DOSE; MENTAL DISEASE; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PANCREATITIS; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; STEATORRHEA; TERATOGENICITY; TRIACYLGLYCEROL BLOOD LEVEL;

ANOVULATION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERANDROGENISM; MODELS, BIOLOGICAL; POLYCYSTIC OVARY SYNDROME;

EID: 50549087657     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.04.009     Document Type: Review

References (239)

1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
2. Ovarian and endometrial function during hormonal contraception. Hum Reprod 16 (2001) 1527-1535
3. Abbott D.H., Barnett D.K., Bruns C.M., and Dumesic D.A. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?. Hum Reprod Update 11 (2005) 357-374
4. Acien P., Mauri M., and Gutierrez M. Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms. Hum Reprod 12 (1997) 423-429
5. Apridonidze T., Essah P.A., Iuorno M.J., and Nestler J.E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 1929-1935
6. Arner P. Effects of testosterone on fat cell lipolysis. Species differences and possible role in polycystic ovarian syndrome. Biochimie 87 (2005) 39-43
7. Aroda V., Ciaraldi T.P., Chang S.A., Dahan M.H., Chang R.J., and Henry R.R. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril 89 (2008) 1200-1208
8. Atiomo W.U., Fox R., Condon J.E., Shaw S., Friend J., Prentice A.G., and Wilkin T.J. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 52 (2000) 487-492
9. Attia G.R., Rainey W.E., and Carr B.R. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 76 (2001) 517-524
10. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 91 (2006) 781-785
11. Badawy A., Mosbah A., and Shady M. Anastrozole or letrozole for ovulation induction in clomiphene-resistant women with polycystic ovarian syndrome: a prospective randomized trial. Fertil Steril 89 (2008) 1209-1212
12. Bahceci M., Aydemir M., and Tuzcu A. Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein, and CRP concentration, and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril 87 (2007) 1363-1368
13. Baillargeon J.P., and Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril 88 (2007) 886-893
14. Banaszewska B., Pawelczyk L., Spaczynski R.Z., Dziura J., and Duleba A.J. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: Prospective, randomized, crossover trial. J Clin Endocrinol Metab 92 (2007) 456-461
15. Barber T.M., McCarthy M.I., Wass J.A., and Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) 65 (2006) 137-145
16. Barnard L., Ferriday D., Guenther N., Strauss B., Balen A.H., and Dye L. Quality of life and psychological well being in polycystic ovary syndrome. Hum Reprod 22 (2007) 2279-2286
17. Barnett J.B., Woods M.N., Lamon-Fava S., Schaefer E.J., McNamara J.R., Spiegelman D., Hertzmark E., Goldin B., Longcope C., and Gorbach S.L. Plasma lipid and lipoprotein levels during the follicular and luteal phases of the menstrual cycle. J Clin Endocrinol Metab 89 (2004) 776-782
18. Barter P.J., Ballantyne C.M., Carmena R., Castro C.M., Chapman M.J., Couture P., de G.J., Durrington P.N., Faergeman O., Frohlich J., Furberg C.D., Gagne C., Haffner S.M., Humphries S.E., Jungner I., Krauss R.M., Kwiterovich P., Marcovina S., Packard C.J., Pearson T.A., Reddy K.S., Rosenson R., Sarrafzadegan N., Sniderman A.D., Stalenhoef A.F., Stein E., Talmud P.J., Tonkin A.M., Walldius G., and Williams K.M. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 (2006) 247-258
19. Berneis K., Rizzo M., Lazzarini V., Fruzzetti F., and Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 92 (2007) 186-189
20. Bickerton A.S., Clark N., Meeking D., Shaw K.M., Crook M., Lumb P., Turner C., and Cummings M.H. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 58 (2005) 151-154
21. Bik W., Baranowska-Bik A., Wolinska-Witort E., Chmielowska M., Martynska L., and Baranowska B. The relationship between metabolic status and levels of adiponectin and ghrelin in lean women with polycystic ovary syndrome. Gynecol Endocrinol 23 (2007) 325-331
22. Boomsma C.M., Eijkemans M.J., Hughes E.G., Visser G.H., Fauser B.C., and Macklon N.S. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 12 (2006) 673-683
23. Bots M.L., Westerink J., Rabelink T.J., and de Koning E.J. Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J 26 (2005) 363-368
24. Brettenthaler N., De G.C., Huber P.R., and Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 3835-3840
25. Brinkworth G.D., Noakes M., Moran L.J., Norman R., and Clifton P.M. Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome. BJOG 113 (2006) 1308-1314
26. Brizzi P., Dessole S., Tonolo G., Capobianco G., Milia L., Puddu L., and Nardo L.G. Effect of ovarian stimulation on plasma lipid and apolipoprotein concentrations in a population of infertile women undergoing IVF/embryo transfer. Reprod Biomed Online 7 (2003) 309-312
27. Broekmans F.J., Knauff E.A., Valkenburg O., Laven J.S., Eijkemans M.J., and Fauser B.C. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG 113 (2006) 1210-1217
28. Bush T.L., Fried L.P., and Barrett-Connor E. Cholesterol, lipoproteins, and coronary heart disease in women. Clin Chem 34 (1988) B60-B70
29. Cagnacci A., Paoletti A.M., Renzi A., Orru M., Pilloni M., Melis G.B., and Volpe A. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab 88 (2003) 3621-3625
30. Carmina E., Orio F., Palomba S., Cascella T., Longo R.A., Colao A.M., Lombardi G., and Lobo R.A. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 152 (2005) 389-394
31. Carnethon M.R., Gulati M., and Greenland P. Prevalence and cardiovascular disease correlates of low cardiorespiratory fitness in adolescents and adults. JAMA 294 (2005) 2981-2988
32. Carr B.R., Breslau N.A., Givens C., Byrd W., Barnett-Hamm C., and Marshburn P.B. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a Clinical Research Center Study. J Clin Endocrinol Metab 80 (1995) 1169-1178
33. Cascella T., Palomba S., Tauchmanova L., Manguso F., Di B.S., Labella D., Giallauria F., Vigorito C., Colao A., Lombardi G., and Orio F. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 91 (2006) 4395-4400
34. Casper R.F., and Mitwally M.F. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 91 (2006) 760-771
35. Castro M.R., Nguyen T.T., and O'Brien T. Clomiphene-induced severe hypertriglyceridemia and pancreatitis. Mayo Clin Proc 74 11 (1999) 1125-1128
36. Cataldo N.A., Abbasi F., McLaughlin T.L., Basina M., Fechner P.Y., Giudice L.C., and Reaven G.M. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum Reprod 21 (2006) 109-120
37. Cenk Sayin N., Gücer F., Balkanli-Kaplan P., Ali Yüce M., and Yardim T. Insulin resistance and lipid profile in women with polycystic appearing ovaries: implications with regard to polycystic ovary syndrome. Gynecol Endocrinol 17 5 (2003) 387-396
38. Christian R.C., Dumesic D.A., Behrenbeck T., Oberg A.L., Sheedy P.F., and Fitzpatrick L.A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 2562-2568
39. Ciampelli M., Leoni F., Lattanzi F., Guido M., Apa R., and Lanzone A. A pilot study of the long-term effects of acipimox in polycystic ovarian syndrome. Hum Reprod 17 (2002) 647-653
40. Ciampelli M., Muzj G., Leoni F., Romualdi D., Belosi C., Cento R.M., and Lanzone A. Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome. J Clin Endocrinol Metab 86 (2001) 5324-5329
41. Clapham J.C., Arch J.R., and Tadayyon M. Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol Ther 89 (2001) 81-121
42. Colilla S., Cox N.J., and Ehrmann D.A. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 86 (2001) 2027-2031
43. Conway G.S., Agrawal R., Betteridge D.J., and Jacobs H.S. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 37 (1992) 119-125
44. Croston G.E., Milan L.B., Marschke K.B., Reichman M., and Briggs M.R. Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology 138 (1997) 3779-3786
45. Cullinane E.M., Yurgalevitch S.M., Saritelli A.L., Herbert P.N., and Thompson P.D. Variations in plasma volume affect total and low-density lipoprotein cholesterol concentrations during the menstrual cycle. Metabolism 44 (1995) 965-971
46. Cussons A.J., Stuckey B.G., and Watts G.F. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 185 (2006) 227-239
47. Dahlgren E., Landin K., Krotkiewski M., Holm G., and Janson P.O. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 13 (1998) 2706-2711
48. De Leo V., la Marca A., and Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24 (2003) 633-667
49. De Leo V., Morgante G., Piomboni P., Musacchio M.C., Petraglia F., and Cianci A. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril 88 (2007) 113-117
50. De Leon R.G., Austin K.L., Richards L., and Guerrero F. Lipid and hormonal profile of Panamanian women during the menstrual cycle. Int J Gynaecol Obstet 39 (1992) 219-226
51. Deeg M.A., Buse J.B., Goldberg R.B., Kendall D.M., Zagar A.J., Jacober S.J., Khan M.A., Perez A.T., and Tan M.H. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 30 (2007) 2458-2464
52. Dejager S., Pichard C., Giral P., Bruckert E., Federspield M.C., Beucler I., and Turpin G. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf) 54 (2001) 455-462
53. Demirel F., Bideci A., Cinaz P., Camurdan M.O., Biberoglu G., Yesilkaya E., and Hasanoglu A. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Clin Endocrinol (Oxf) 67 (2007) 129-134
54. Diamanti-Kandarakis E., Mitrakou A., Raptis S., Tolis G., and Duleba A.J. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 83 (1998) 2699-2705
55. Diamanti-Kandarakis E., Papavassiliou A.G., Kandarakis S.A., and Chrousos G.P. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 18 (2007) 280-285
56. Dronavalli S., and Ehrmann D.A. Pharmacologic therapy of polycystic ovary syndrome. Clin Obstet Gynecol 50 (2007) 244-254
57. Drucker D.J. The role of gut hormones in glucose homeostasis. J Clin Invest 117 (2007) 24-32
58. Duleba A.J., Banaszewska B., Spaczynski R.Z., and Pawelczyk L. Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril 85 (2006) 996-1001
59. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18 (1997) 774-800
60. Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril 86 Suppl 1 (2006) S13-S14
61. Dunaif A., Wu X., Lee A., and Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 281 (2001) E392-E399
62. Eckardstein von E.A., Nofer J.R., and Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21 (2001) 13-27
63. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 352 (2005) 1223-1236
64. Ehrmann D.A., Liljenquist D.R., Kasza K., Azziz R., Legro R.S., and Ghazzi M.N. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 48-53
65. Ek I., Arner P., Ryden M., Holm C., Thorne A., Hoffstedt J., and Wahrenberg H. A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes 51 (2002) 484-492
66. Elter K., Imir G., and Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 17 (2002) 1729-1737
67. Elting M.W., Korsen T.J., Bezemer P.D., and Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 16 (2001) 556-560
68. Essah P.A., Wickham E.P., and Nestler J.E. The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol 50 (2007) 205-225
69. Faloia E., Canibus P., Gatti C., Frezza F., Santangelo M., Garrapa G.G., and Boscaro M. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest 27 (2004) 424-429
70. Falsetti L., and Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception 42 (1990) 611-619
71. Faulds G., Ryden M., Ek I., Wahrenberg H., and Arner P. Mechanisms behind lipolytic catecholamine resistance of subcutaneous fat cells in the polycystic ovarian syndrome. J Clin Endocrinol Metab 88 (2003) 2269-2273
72. Fenkci V., Fenkci S., Yilmazer M., and Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 80 (2003) 123-127
73. Filippatos T.D., Gazi I.F., Liberopoulos E.N., Athyros V.G., Elisaf M.S., Tselepis A.D., and Kiortsis D.N. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 193 (2007) 428-437
74. Filippatos T.D., Liberopoulos E.N., Kostapanos M., Gazi I.F., Papavasiliou E.C., Kiortsis D.N., Tselepis A.D., and Elisaf M.S. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 10 (2008) 476-483
75. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 91 (2006) 786-789
76. Froment P., Fabre S., Dupont J., Pisselet C., Chesneau D., Staels B., and Monget P. Expression and functional role of peroxisome proliferator-activated receptor-gamma in ovarian folliculogenesis in the sheep. Biol Reprod 69 (2003) 1665-1674
77. Gambineri A., Pelusi C., Genghini S., Morselli-Labate A.M., Cacciari M., Pagotto U., and Pasquali R. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 60 (2004) 241-249
78. Gambineri A., Patton L., Vaccina A., Cacciari M., Morselli-Labate A.M., Cavazza C., Pagotto U., and Pasquali R. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 91 (2006) 3970-3980
79. Gambineri A., Vicennati V., Genghini S., Tomassoni F., Pagotto U., Pasquali R., and Walker B.R. Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 2295-2302
80. Ghazeeri G., Kutteh W.H., Bryer-Ash M., Haas D., and Ke R.W. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 79 (2003) 562-566
81. Giallauria F., Palomba S., Manguso F., Vitelli A., Maresca L., Tafuri D., Lombardi G., Colao A., Vigorito C., and Orio F. Abnormal heart rate recovery after maximal cardiopulmonary exercise stress testing in young overweight women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 68 (2008) 88-93
82. Gill J.M. Physical activity, cardiorespiratory fitness and insulin resistance: a short update. Curr Opin Lipidol 18 (2007) 47-52
83. Ginsberg H.N., Zhang Y.L., and Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 36 (2005) 232-240
84. Glintborg D., Frystyk J., Hojlund K., Andersen K.K., Henriksen J.E., Hermann A.P., Hagen C., Flyvbjerg A., and Andersen M. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf) 68 (2008) 165-174
85. Glintborg D., Hermann A.P., Andersen M., Hagen C., Beck-Nielsen H., Veldhuis J.D., and Henriksen J.E. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril 86 (2006) 385-397
86. Glueck C.J., Aregawi D., Agloria M., Winiarska M., Sieve L., and Wang P. Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. Metabolism 55 (2006) 1582-1589
87. Glueck C.J., Goldenberg N., Streicher P., and Wang P. Metformin and gestational diabetes. Curr Diab Rep 3 (2003) 303-312
88. Glueck C.J., Moreira A., Goldenberg N., Sieve L., and Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 18 (2003) 1618-1625
89. Goldenberg N.M., Wang P., and Glueck C.J. An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. Clin Chim Acta 332 (2003) 11-19
90. Groen A.K., Oude Elferink R.P., Verkade H.J., and Kuipers F. The ins and outs of reverse cholesterol transport. Ann Med 36 (2004) 135-145
91. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith Jr. S.C., Spertus J.A., and Costa F. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 112 (2005) 2735-2752
92. Guido M., Romualdi D., Giuliani M., Suriano R., Selvaggi L., Apa R., and Lanzone A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 89 (2004) 2817-2823
93. Guo L., and Tabrizchi R. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacol Ther 111 (2006) 145-173
94. Guzelmeric K., Alkan N., Pirimoglu M., Unal O., and Turan C. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Gynecol Endocrinol (2007) 1-6
95. Haas D.A., Carr B.R., and Attia G.R. Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. Fertil Steril 79 (2003) 469-481
96. Harborne L., Fleming R., Lyall H., Norman J., and Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 361 (2003) 1894-1901
97. Harborne L., Fleming R., Lyall H., Sattar N., and Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 4116-4123
98. Heiling V.J., and Jensen M.D. Free fatty acid metabolism in the follicular and luteal phases of the menstrual cycle. J Clin Endocrinol Metab 74 (1992) 806-810
99. Herbst K.L., Amory J.K., Brunzell J.D., Chansky H.A., and Bremner W.J. Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. Am J Physiol Endocrinol Metab 284 (2003) E1112-E1118
100. Hoeger K.M. Obesity and lifestyle management in polycystic ovary syndrome. Clin Obstet Gynecol 50 (2007) 277-294
101. Hoeger K.M., Kochman L., Wixom N., Craig K., Miller R.K., and Guzick D.S. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 82 (2004) 421-429
102. Holte J., Bergh T., Berne C., and Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 41 (1994) 463-471
103. Huber-Buchholz M.M., Carey D.G., and Norman R.J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 84 (1999) 1470-1474
104. Huxley R., Barzi F., and Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332 (2006) 73-78
105. Ibanez L., and De Zegher F. Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 88 (2003) 4720-4724
106. Ibanez L., Lopez-Bermejo A., del Rio L., Enriquez G., Valls C., and De Zegher F. Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. J Clin Endocrinol Metab 92 (2007) 1710-1714
107. Ibanez L., Valls C., Cabre S., and De Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. J Clin Endocrinol Metab 89 (2004) 4716-4720
108. Ibanez L., Valls C., Marcos M.V., Ong K., Dunger D.B., and De Zegher F. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. J Clin Endocrinol Metab 89 (2004) 4331-4337
109. Izquierdo D., Foyouzi N., Kwintkiewicz J., and Duleba A.J. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 82 Suppl 3 (2004) 1193-1197
110. Jauhiainen M., Metso J., Pahlman R., Blomqvist S., van Tol A., and Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 268 (1993) 4032-4036
111. Jaworski K., Sarkadi-Nagy E., Duncan R.E., Ahmadian M., and Sul H.S. Regulation of triglyceride metabolism. IV. Hormonal Regulation of Lipolysis in Adipose Tissue. Am J Physiol Gastrointest Liver Physiol 293 (2007) G1-G4
112. Jayagopal V., Kilpatrick E.S., Holding S., Jennings P.E., and Atkin S.L. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 90 (2005) 729-733
113. Jeffrey C.R., and Coffler M.S. Polycystic ovary syndrome: early detection in the adolescent. Clin Obstet Gynecol 50 (2007) 178-187
114. Jones D.Y., Judd J.T., Taylor P.R., Campbell W.S., and Nair P.P. Menstrual cycle effect on plasma lipids. Metabolism 37 (1988) 1-2
115. Kauppinen-Makelin R., Kuusi T., Ylikorkala O., and Tikkanen M.J. Contraceptives containing desogestrel or levonorgestrel have different effects on serum lipoproteins and post-heparin plasma lipase activities. Clin Endocrinol (Oxf) 36 (1992) 203-209
116. Kelly C.J., Speirs A., Gould G.W., Petrie J.R., Lyall H., and Connell J.M. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 742-746
117. Keskin M., Songür Y., and Işler M. Clomiphene-induced acute pancreatitis without hypertriglyceridemia. Am J Med Sci 333 3 (2007) 194-196
118. Kilicdag E.B., Bagis T., Zeyneloglu H.B., Tarim E., Aslan E., Haydardedeoglu B., and Erkanli S. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 20 (2005) 894-899
119. Klipping C., and Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 71 (2005) 409-416
120. Kokkinos P.F., Holland J.C., Narayan P., Colleran J.A., Dotson C.O., and Papademetriou V. Miles run per week and high-density lipoprotein cholesterol levels in healthy, middle-aged men. A Dose-Response Relationship. Arch Intern Med 155 (1995) 415-420
121. Kontush A., and Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58 (2006) 342-374
122. Koo Y.A., Shin S.Y., Yoon B.K., and Choi D. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. Gynecol Endocrinol (2007) 1-7
123. Korytkowski M.T., Mokan M., Horwitz M.J., and Berga S.L. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 80 (1995) 3327-3334
124. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62 (2000) 29-38
125. Kravariti M., Naka K.K., Kalantaridou S.N., Kazakos N., Katsouras C.S., Makrigiannakis A., Paraskevaidis E.A., Chrousos G.P., Tsatsoulis A., and Michalis L.K. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 5088-5095
126. Krentz A.J., von M.D., and Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause 14 (2007) 284-292
127. Kumar S., Durrington P.N., Bhatnagar D., and Laing I. Suppression of non-esterified fatty acids to treat type a insulin resistance syndrome. Lancet 343 (1994) 1073-1074
128. Kwintkiewicz J., Foyouzi N., Piotrowski P., Rzepczynska I., and Duleba A.J. Mevastatin inhibits proliferation of rat ovarian theca-interstitial cells by blocking the mitogen-activated protein kinase pathway. Fertil Steril 86 Suppl 4 (2006) 1053-1058
129. Lakhani K., Hardiman P., and Seifalian A.M. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 175 (2004) 353-359
130. Langer C., Gansz B., Goepfert C., Engel T., Uehara Y., von D.G., Jansen H., Assmann G., and von E.A. Testosterone up-regulates scavenger receptor bi and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 296 (2002) 1051-1057
131. Laven J.S., and Fauser B.C. What role of estrogens in ovarian stimulation. Maturitas 54 (2006) 356-362
132. Lebinger T.G. Metformin and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 14 (2007) 132-140
133. Legro R.S., Azziz R., Ehrmann D., Fereshetian A.G., O'Keefe M., and Ghazzi M.N. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 88 (2003) 5137-5144
134. Legro R.S., Barnhart H.X., Schlaff W.D., Carr B.R., Diamond M.P., Carson S.A., Steinkampf M.P., Coutifaris C., McGovern P.G., Cataldo N.A., Gosman G.G., Nestler J.E., Giudice L.C., Leppert P.C., and Myers E.R. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356 (2007) 551-566
135. Legro R.S., Blanche P., Krauss R.M., and Lobo R.A. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertil Steril 72 (1999) 990-995
136. Legro R.S., Castracane V.D., and Kauffman R.P. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 59 (2004) 141-154
137. Legro R.S., Kunselman A.R., and Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111 (2001) 607-613
138. Leibel N.I., Baumann E.E., Kocherginsky M., and Rosenfield R.L. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. J Clin Endocrinol Metab 91 (2006) 1275-1283
139. Lemay A., Dodin S., Turcot L., Dechene F., and Forest J.C. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod 21 (2006) 121-128
140. Lewis G.F., Carpentier A., Adeli K., and Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23 (2002) 201-229
141. Li T.Y., Rana J.S., Manson J.E., Willett W.C., Stampfer M.J., Colditz G.A., Rexrode K.M., and Hu F.B. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation 113 (2006) 499-506
142. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
143. Lindholm A., Bixo M., Bjorn I., Wolner-Hanssen P., Eliasson M., Larsson A., Johnson O., and Poromaa I.S. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil Steril 89 (2008) 1221-1228
144. Lo J.C., Feigenbaum S.L., Yang J., Pressman A.R., Selby J.V., and Go A.S. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 1357-1363
145. Lopez L.M., Grimes D.A., and Schulz K.F. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst RevCD006133 (2007)
146. Lord J.M., Flight I.H., and Norman R.J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst RevCD003053 (2003)
147. Lord J.M., Flight I.H., and Norman R.J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327 (2003) 951-953
148. Lyons Wall P.M., Choudhury N., Gerbrandy E.A., and Truswell A.S. Increase of high-density lipoprotein cholesterol at ovulation in healthy women. Atherosclerosis 105 (1994) 171-178
149. Macut D., Damjanovic S., Panidis D., Spanos N., Glisic B., Petakov M., Rousso D., Kourtis A., Bjekic J., and Milic N. Oxidised low-density lipoprotein concentration - Early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol 155 (2006) 131-136
150. Magkos F., Patterson B.W., Mohammed B.S., Klein S., and Mittendorfer B. Women produce fewer but triglyceride-richer very low-density lipoproteins than men. J Clin Endocrinol Metab 92 (2007) 1311-1318
151. Mai K., Andres J., Bobbert T., Maser-Gluth C., Mohlig M., Bahr V., Pfeiffer A.F., Spranger J., and Diederich S. Rosiglitazone decreases 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue. Clin Endocrinol (Oxf) 67 (2007) 419-425
152. Mansfield R., Galea R., Brincat M., Hole D., and Mason H. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 79 (2003) 956-962
153. Mastorakos G., Koliopoulos C., and Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 77 (2002) 919-927
154. Mather K.J., Verma S., Corenblum B., and Anderson T.J. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J Clin Endocrinol Metab 85 (2000) 1851-1856
155. Mattsson L.A., Silfverstolpe G., and Samsioe G. Lipid composition of serum lipoproteins in relation to gonadal hormones during the normal menstrual cycle. Eur J Obstet Gynecol Reprod Biol 17 (1984) 327-335
156. McSweeney J.C., Cody M., O'Sullivan P., Elberson K., Moser D.K., and Garvin B.J. Women's early warning symptoms of acute myocardial infarction. Circulation 108 (2003) 2619-2623
157. Meyer C., McGrath B.P., Cameron J., Kotsopoulos D., and Teede H.J. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 4630-4635
158. Meyer C., McGrath B.P., and Teede H.J. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 90 (2005) 5711-5716
159. Meyer C., McGrath B.P., and Teede H.J. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30 (2007) 471-478
160. Meyer E., Westerveld H.T., de Ruyter-Meijstek F.C., van Greevenbroek M.M., Rienks R., van Rijn H.J., Erkelens D.W., and de Bruin T.W. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis 124 (1996) 221-235
161. Misugi T., Ozaki K., El B.K., Tokuyama O., Honda K., and Ishiko O. Insulin-lowering agents inhibit synthesis of testosterone in ovaries of DHEA-induced PCOS rats. Gynecol Obstet Invest 61 (2006) 208-215
162. Mitchell M., Armstrong D.T., Robker R.L., and Norman R.J. Adipokines: implications for female fertility and obesity. Reproduction 130 (2005) 583-597
163. Moll E., Bossuyt P.M., Korevaar J.C., Lambalk C.B., and van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 332 (2006) 1485
164. Mora S., Redberg R.F., Sharrett A.R., and Blumenthal R.S. Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores. Circulation 112 (2005) 1566-1572
165. Moran L.J., Brinkworth G., Noakes M., and Norman R.J. Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online 12 (2006) 569-578
166. Morin-Papunen L.C., Vauhkonen I., Koivunen R.M., Ruokonen A., Martikainen H.K., and Tapanainen J.S. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 85 (2000) 3161-3168
167. Muesing R.A., Forman M.R., Graubard B.I., Beecher G.R., Lanza E., McAdam P.A., Campbell W.S., and Olson B.R. Cyclic changes in lipoprotein and apolipoprotein levels during the menstrual cycle in healthy premenopausal women on a controlled diet. J Clin Endocrinol Metab 81 (1996) 3599-3603
168. Nader S., and Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod 22 (2007) 317-322
169. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
170. Norman R.J., Masters S.C., Hague W., Beng C., Pannall P., and Wang J.X. Metabolic approaches to the subclassification of polycystic ovary syndrome. Fertil Steril 63 (1995) 329-335
171. Norman R.J., Noakes M., Wu R., Davies M.J., Moran L., and Wang J.X. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 10 (2004) 267-280
172. Olszanecka-Glinianowicz M., Banas M., Zahorska-Markiewicz B., Janowska J., Kocelak P., Madej P., and Klimek K. Is the polycystic ovary syndrome associated with chronic inflammation per se?. Eur J Obstet Gynecol Reprod Biol 133 (2007) 197-202
173. Oram J.F. ATP-binding cassette transporter A1 and cholesterol trafficking. Curr Opin Lipidol 13 (2002) 373-381
174. Orio Jr. F., Giallauria F., Palomba S., Cascella T., Manguso F., Vuolo L., Russo T., Tolino A., Lombardi G., Colao A., and Vigorito C. Cardiopulmonary impairment in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 2967-2971
175. Orio Jr. F., Palomba S., Cascella T., De S.B., Di B.S., Russo T., Labella D., Zullo F., Lombardi G., and Colao A. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 4588-4593
176. Orio Jr. F., Palomba S., Cascella T., De S.B., Manguso F., Savastano S., Russo T., Tolino A., Zullo F., Lombardi G., Azziz R., and Colao A. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 90 (2005) 6072-6076
177. Orio Jr. F., Palomba S., Spinelli L., Cascella T., Tauchmanova L., Zullo F., Lombardi G., and Colao A. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89 (2004) 3696-3701
178. Owen A.J., Roach P.D., and Abbey M. Regulation of low-density lipoprotein receptor activity by estrogens and phytoestrogens in a HepG2 cell model. Ann Nutr Metab 48 (2004) 269-275
179. Padwal R.S., and Majumdar S.R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369 (2007) 71-77
180. Panidis D., Farmakiotis D., Rousso D., Kourtis A., Katsikis I., and Krassas G. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril 89 (2008) 899-906
181. Paradisi G., Steinberg H.O., Shepard M.K., Hook G., and Baron A.D. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 576-580
182. Parsey K.S., and Pong A. An open-label, multicenter study to evaluate yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 61 (2000) 105-111
183. Parulkar A.A., Pendergrass M.L., Granda-Ayala R., Lee T.R., and Fonseca V.A. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134 (2001) 61-71
184. Pierpoint T., McKeigue P.M., Isaacs A.J., Wild S.H., and Jacobs H.S. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51 (1998) 581-586
185. Pirwany I.R., Fleming R., Greer I.A., Packard C.J., and Sattar N. Lipids and Lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 54 (2001) 447-453
186. Qin K.N., and Rosenfield R.L. Role of cytochrome P450c17 in polycystic ovary syndrome. Mol Cell Endocrinol 145 (1998) 111-121
187. Rajkhowa M., Neary R.H., Kumpatla P., Game F.L., Jones P.W., Obhrai M.S., and Clayton R.N. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 82 (1997) 3389-3394
188. Randeva H.S., Lewandowski K.C., Drzewoski J., Brooke-Wavell K., O'Callaghan C., Czupryniak L., Hillhouse E.W., and Prelevic G.M. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 4496-4501
189. Reitsma J.B., Castro C.M., de Bruin T.W., and Erkelens D.W. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 43 (1994) 293-298
190. Robinson S., Henderson A.D., Gelding S.V., Kiddy D., Niththyananthan R., Bush A., Richmond W., Johnston D.G., and Franks S. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf) 44 (1996) 277-284
191. Rucker D., Padwal R., Li S.K., Curioni C., and Lau D.C. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 335 (2007) 1194
192. Ryden M., Jocken J., van V H., Dicker A., Hoffstedt J., Wiren M., Blomqvist L., Mairal A., Langin D., Blaak E., and Arner P. Comparative studies of the role of hormone-sensitive lipase and adipose triglyceride lipase in human fat cell lipolysis. Am J Physiol Endocrinol Metab 292 (2007) E1847-E1855
193. Sabuncu T., Harma M., Harma M., Nazligul Y., and Kilic F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil Steril 80 (2003) 1199-1204
194. Sam S., Legro R.S., Essah P.A., Apridonidze T., and Dunaif A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A 103 (2006) 7030-7035
195. Sampson M., Kong C., Patel A., Unwin R., and Jacobs H.S. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 45 (1996) 623-629
196. Schaefer E.J., Foster D.M., Zech L.A., Lindgren F.T., Brewer Jr. H.B., and Levy R.I. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 57 (1983) 262-267
197. Schaefer E.J., Lamon-Fava S., Cohn S.D., Schaefer M.M., Ordovas J.M., Castelli W.P., and Wilson P.W. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham offspring study. J Lipid Res 35 (1994) 779-792
198. Seow K.M., Juan C.C., Wu L.Y., Hsu Y.P., Yang W.M., Tsai Y.L., Hwang J.L., and Ho L.T. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum Reprod 19 (2004) 48-53
199. Sharma A.M., and Staels B. Review: peroxisome proliferator-activated receptor gamma and adipose tissue-Understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 92 (2007) 386-395
200. Silfen M.E., Denburg M.R., Manibo A.M., Lobo R.A., Jaffe R., Ferin M., Levine L.S., and Oberfield S.E. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 88 (2003) 4682-4688
201. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195
202. Slopien R., Lewandowski K., Kolacz E., Zawilska K., and Warenik-Szymankiewicz A. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity. Gynecol Endocrinol 22 (2006) 651-654
203. Solomon C.G., Hu F.B., Dunaif A., Rich-Edwards J.E., Stampfer M.J., Willett W.C., Speizer F.E., and Manson J.E. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 87 (2002) 2013-2017
204. Sorensen M.B., Franks S., Robertson C., Pennell D.J., and Collins P. Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors. Clin Endocrinol (Oxf) 65 (2006) 655-659
205. Sorva R., Kuusi T., Dunkel L., and Taskinen M.R. Effects of endogenous sex steroids on serum lipoproteins and postheparin plasma lipolytic enzymes. J Clin Endocrinol Metab 66 (1988) 408-413
206. Stankiewicz M., and Norman R. Diagnosis and management of polycystic ovary syndrome: a practical guide. Drugs 66 (2006) 903-912
207. Talbott E., Clerici A., Berga S.L., Kuller L., Guzick D., Detre K., Daniels T., and Engberg R.A. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 51 (1998) 415-422
208. Talbott E.O., Zborowski J.V., Rager J.R., Boudreaux M.Y., Edmundowicz D.A., and Guzick D.S. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 5454-5461
209. Tang T., Glanville J., Hayden C.J., White D., Barth J.H., and Balen A.H. Combined Lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 21 (2006) 80-89
210. Tarkun I., Canturk Z., Arslan B.C., Turemen E., and Tarkun P. The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J 51 (2004) 467-472
211. Tarkun I., Cetinarslan B., Turemen E., Sahin T., Canturk Z., and Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 153 (2005) 115-121
212. Ten S., and Maclaren N. Insulin resistance syndrome in children. J Clin Endocrinol Metab 89 (2004) 2526-2539
213. Tikkanen M.J., Kuusi T., Nikkila E.A., and Stenman U.H. Variation of postheparin plasma hepatic lipase by menstrual cycle. Metabolism 35 (1986) 99-104
214. Tiras M.B., Yalcin R., Noyan V., Maral I., Yildirim M., Dortlemez O., and Daya S. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Hum Reprod 14 (1999) 1949-1952
215. de Torbal T.A., Boersma E., Kors J.A., van Herpen G., Deckers J.W., van der Kuip D.A., Stricker B.H., Hofman A., and Witteman J.C. Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam study. Eur Heart J 27 (2006) 729-736
216. Torgerson J.S., Hauptman J., Boldrin M.N., and Sjostrom L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27 (2004) 155-161
217. Tzotzas T., Samara M., Constantinidis T., Tziomalos K., and Krassas G. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome. Angiology 58 (2007) 26-33
218. Valkenburg O., Steegers-Theunissen R.P.M., Smedts H.P.M., Dallinga-Thie G.M., Fauser B.C.J.M., Westerveld E.H., and Laven J.S.E. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 93 2 (2008) 470-476
219. Velazquez M.E., Bellabarba G.A., Mendoza S., and Sanchez L. Postprandial triglyceride response in patients with polycystic ovary syndrome: relationship with waist-to-hip ratio and insulin. Fertil Steril 74 (2000) 1159-1163
220. Venturoli S., Marescalchi O., Colombo F.M., Macrelli S., Ravaioli B., Bagnoli A., Paradisi R., and Flamigni C. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 84 (1999) 1304-1310
221. Vigorito C., Giallauria F., Palomba S., Cascella T., Manguso F., Lucci R., De L.A., Tafuri D., Lombardi G., Colao A., and Orio F. Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 92 (2007) 1379-1384
222. Villaseca P., Hormaza P., Cardenas I., Oestreicher E., and Arteaga E. Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes. Eur J Contracept Reprod Health Care 9 (2004) 155-165
223. Vink J.M., Sadrzadeh S., Lambalk C.B., and Boomsma D.I. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 91 (2006) 2100-2104
224. Vrbikova J., and Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11 (2005) 277-291
225. Vrbikova J., Hill M., Dvorakova K., Stanicka S., Vondra K., and Starka L. Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome. Gynecol Obstet Invest 58 (2004) 36-41
226. Vrbikova J., Stanicka S., Dvorakova K., Hill M., Vondra K., Bendlova B., and Starka L. Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjunction with peroral cyproterone acetate in women with polycystic ovary syndrome. Eur J Endocrinol 150 (2004) 215-223
227. Vryonidou A., Papatheodorou A., Tavridou A., Terzi T., Loi V., Vatalas I.A., Batakis N., Phenekos C., and Di onyssiou-Asteriou A. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 2740-2746
228. Wahrenberg H., Ek I., Reynisdottir S., Carlstrom K., Bergqvist A., and Arner P. Divergent effects of weight reduction and oral anticonception treatment on adrenergic lipolysis regulation in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 84 (1999) 2182-2187
229. Walsh B.W., and Sacks F.M. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism. J Clin Invest 91 (1993) 2126-2132
230. Welt C.K., Gudmundsson J.A., Arason G., Adams J., Palsdottir H., Gudlaugsdottir G., Ingadottir G., and Crowley W.F. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 91 (2006) 4842-4848
231. Wirth A., and Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286 (2001) 1331-1339
232. Xita N., and Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J Clin Endocrinol Metab 91 (2006) 1660-1666
233. Yarali H., Yildirir A., Aybar F., Kabakci G., Bukulmez O., Akgul E., and Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 76 (2001) 511-516
234. Yildirim B., Sabir N., and Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril 79 (2003) 1358-1364
235. Yildiz B.O., Haznedaroglu I.C., Kirazli S., and Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 87 (2002) 3871-3875
236. Yilmaz M., Biri A., Bukan N., Karakoc A., Sancak B., Toruner F., and Pasaoglu H. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 20 (2005) 258-263
237. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., and Moller D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108 (2001) 1167-1174
238. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation 60 (1979) 473-485
239. Zulian E., Sartorato P., Benedini S., Baro G., Armanini D., Mantero F., and Scaroni C. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest 28 (2005) 49-53